Gene: FANCL

55120
FAAP43|PHF9|POG
FA complementation group L
protein-coding
2p16.1
Ensembl:ENSG00000115392 MIM:608111 Vega:OTTHUMG00000129349 UniprotKB:Q9NW38
NG_007418.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.959e-2 (AD)  2.523e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PCMTD20.868
MLH30.866
FAR10.861
USP480.855
IFT800.852
CPOX0.847
ZNF5290.846
ZNF6380.845
ATG120.843
CNOT20.842

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.483
OR4F29-0.461
PLA2G5-0.374
WNT7B-0.358
ENDOU-0.35
SYPL2-0.333
DIO2-0.328
HES5-0.305
RASSF10-0.299
PYGM-0.296

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCL mRNA"19167446
C4711094(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline"4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline results in decreased expression of FANCL mRNA"19934314
D000082AcetaminophenAcetaminophen results in decreased expression of FANCL mRNA21420995
D000082AcetaminophenAcetaminophen affects the expression of FANCL mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of FANCL mRNA19770486
D001205Ascorbic Acid[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA26424790
D001280AtrazineAtrazine results in increased expression of FANCL mRNA25929836
D001280AtrazineAtrazine results in decreased expression of FANCL mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FANCL mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of FANCL mRNA22228805
C031463beta-glycerophosphoric acid[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA26424790
C044887beta-methylcholinebeta-methylcholine affects the expression of FANCL mRNA21179406
C006780bisphenol Abisphenol A affects the expression of FANCL mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of FANCL mRNA29275510
D002220CarbamazepineCarbamazepine affects the expression of FANCL mRNA24752500
C018021cobaltous chloridecobaltous chloride results in decreased expression of FANCL mRNA19376846
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCL mRNA"19167446
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in increased expression of FANCL mRNA19167446
C408982CPG-oligonucleotideCPG-oligonucleotide results in decreased expression of FANCL mRNA21878529
D016572CyclosporineCyclosporine results in decreased expression of FANCL mRNA20106945|2556210
D003907Dexamethasone[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA26424790
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of FANCL mRNA17361019|2126653
D004008DiclofenacDiclofenac affects the expression of FANCL mRNA24752500
C000944dicrotophosdicrotophos results in decreased expression of FANCL mRNA28302478
D004317DoxorubicinFANCL protein affects the susceptibility to Doxorubicin16217747
D006046GoldGold results in decreased expression of FANCL mRNA25523186
C056493imiquimodimiquimod results in decreased expression of FANCL mRNA21878529
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of FANCL mRNA25613284
C045463leflunomideleflunomide results in decreased expression of FANCL mRNA28988120
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of FANCL mRNA26011545
C022838nickel chloridenickel chloride results in decreased expression of FANCL mRNA17312168
D017239PaclitaxelFANCL protein affects the susceptibility to Paclitaxel16217747
D052638Particulate MatterParticulate Matter results in increased expression of FANCL mRNA24769257
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of FANCL mRNA19710929
C006253pirinixic acidpirinixic acid results in increased expression of FANCL mRNA17950772|1830175
C006253pirinixic acidPPARA protein promotes the reaction [pirinixic acid results in increased expression of FANCL mRNA]17950772
D010894PiroxicamPiroxicam results in increased expression of FANCL mRNA21858171
D011441PropylthiouracilPropylthiouracil results in increased expression of FANCL mRNA24780913
D011794QuercetinQuercetin results in decreased expression of FANCL mRNA21632981
C031389resorcinolresorcinol results in increased expression of FANCL mRNA22623647
C059514resveratrol[Coumestrol co-treated with resveratrol] results in increased expression of FANCL mRNA19167446
D012999SomanSoman results in decreased expression of FANCL mRNA19281266
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FANCL mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FANCL mRNA21570461
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of FANCL mRNA25613284
D019772TopotecanFANCL protein affects the susceptibility to Topotecan16217747
C057693troglitazonetroglitazone results in decreased expression of FANCL mRNA19140230
D014635Valproic AcidValproic Acid results in decreased expression of FANCL mRNA19101580
D014747VinblastineFANCL protein affects the susceptibility to Vinblastine16217747

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004842ubiquitin-protein transferase activity-IDA16916645  19111657  
GO:0004842ubiquitin-protein transferase activity-ISS-  
GO:0005515protein binding-IPI24389026  25416956  
GO:0031625ubiquitin protein ligase binding-IPI16916645  17938197  19111657  
GO:0046872metal ion binding-IEA-  
GO:0061630ubiquitin protein ligase activity-IDA19589784  
GO ID GO Term Qualifier Evidence PubMed
GO:0006281DNA repair-IMP16916645  
GO:0006513protein monoubiquitination-IDA16916645  24389026  
GO:0006974cellular response to DNA damage stimulus-IMP16916645  
GO:0007276gamete generation-IEA-  
GO:0036297interstrand cross-link repair-TAS-  
GO:0042127regulation of cell proliferation-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005635nuclear envelope-IEA-  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IEA-  
GO:0016604nuclear body-IDA-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0043240Fanconi anaemia nuclear complex-IDA20347428  22343915  
KEGG ID KEGG Term
hsa04120Ubiquitin mediated proteolysis
Reactome ID Reactome Term Evidence
R-HSA-6783310Fanconi Anemia PathwayTAS
R-HSA-73894DNA RepairTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23978819Generalization of adiposity genetic loci to US Hispanic women. (2013 Aug 26)Graff MNutr Diabetes